- Home
- NMT vs CLYM Comparison
NMT vs CLYM Comparison
Compare NMT & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- CLYM
- Stock Information
- Founded
- NMT 1993
- CLYM 2018
- Country
- NMT United States
- CLYM United States
- Employees
- NMT N/A
- CLYM N/A
- Industry
- NMT Finance/Investors Services
- CLYM
- Sector
- NMT Finance
- CLYM
- Exchange
- NMT Nasdaq
- CLYM NYSE
- Market Cap
- NMT 110.6M
- CLYM 101.6M
- IPO Year
- NMT N/A
- CLYM 2021
- Fundamental
- Price
- NMT $11.80
- CLYM $1.22
- Analyst Decision
- NMT
- CLYM
- Analyst Count
- NMT 0
- CLYM 0
- Target Price
- NMT N/A
- CLYM N/A
- AVG Volume (30 Days)
- NMT 19.1K
- CLYM 172.8K
- Earning Date
- NMT 01-01-0001
- CLYM 03-25-2025
- Dividend Yield
- NMT 3.21%
- CLYM N/A
- EPS Growth
- NMT N/A
- CLYM N/A
- EPS
- NMT N/A
- CLYM N/A
- Revenue
- NMT N/A
- CLYM N/A
- Revenue This Year
- NMT N/A
- CLYM N/A
- Revenue Next Year
- NMT N/A
- CLYM N/A
- P/E Ratio
- NMT N/A
- CLYM N/A
- Revenue Growth
- NMT N/A
- CLYM N/A
- 52 Week Low
- NMT $9.05
- CLYM $1.20
- 52 Week High
- NMT $10.93
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- NMT 53.11
- CLYM N/A
- Support Level
- NMT $11.72
- CLYM N/A
- Resistance Level
- NMT $11.78
- CLYM N/A
- Average True Range (ATR)
- NMT 0.09
- CLYM 0.00
- MACD
- NMT -0.01
- CLYM 0.00
- Stochastic Oscillator
- NMT 43.33
- CLYM 0.00
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.